Clinical trial Recruiting at 2 sites Phase 2 Interventional Ages 18 to 70

Evaluating SAMe for improving liver function in patients with alcoholic cirrhosis

Official title: A Multi-center, Randomized, Placebo-controlled Trial of S-Adenosylmethionine (SAMe) in Patients With Alcoholic Cirrhosis

Run by Indiana University · NCT04250259 · Data updated 2026-11-12

This study is testing if a supplement called SAMe can help improve liver function in people with alcoholic cirrhosis.

Quick facts

PhasePhase 2
Study typeInterventional
Ages18 Years to 70 Years
SexAll
Enrollment196 (estimated)
SponsorIndiana University
Academic / other
Locations2 sites (Los Angeles, California and 1 other locations)
StatusRecruiting
StartedOctober 22, 2020
Main results expectedMarch 1, 2027
Study endsMarch 1, 2027
Registry record updatedMarch 31, 2026
Trial IDNCT04250259 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults aged 18 to 70 with alcoholic cirrhosis classified as Child Class A or B.

Probably not a fit

Patients with active infections or severe co-existing liver conditions may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized, double-blind, placebo-controlled trial aims to assess the effects of S-adenosylmethionine (SAMe) on liver function in patients diagnosed with alcoholic cirrhosis classified as Child Class A or B. Participants will receive either SAMe or a placebo to determine if the supplement can improve liver function and reduce all-cause mortality. The study will include individuals aged 18 to 70 years, with specific inclusion and exclusion criteria to ensure appropriate patient selection. The primary objective is to establish a relationship between SAMe supplementation and liver health outcomes.

Why it matters

Potential benefit: If successful, this study could lead to improved liver function and reduced mortality rates in patients with alcoholic cirrhosis.

How similar studies have gone: Other studies have explored SAMe's effects on liver health, but this specific approach in alcoholic cirrhosis is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion criteria for patients with alcoholic cirrhosis

1. Evidence of cirrhosis as per clinical signs and/or noninvasive transient elastography (Fibroscan®), computed tomography, magnetic resonance imaging including MRI elastography compatible with cirrhosis and/or histopathology by biopsy and
2. subjects with clinical presentation either in Child Class A or B at the time of enrollment
3. individuals 18 to 70 years old and may or may not consume alcohol during study.

Inclusion criteria for healthy control :

) individuals 18 to 70 years old (2) able to provide informed consent (3) subjects do not consume any alcohol or those who drink \< 50 grams per day on average in women and \< 80 grams per day on average in men (4) subjects are healthy without underlying acute or chronic medical conditions.

Exclusion criteria for patients with alcoholic cirrhosis

1. Active infection as evidenced by positive urine culture, blood culture, or pneumonia,
2. Known co-existing infection with hepatitis C, hepatitis B, or HIV
3. Significant systemic or major illness including chronic obstructive pulmonary disease, congestive heart failure, and renal failure that in the opinion of the Investigator would preclude the patient from participating in and completing the study
4. Gastrointestinal bleeding within the prior 28 days3
5. Participation in another investigational drug, biologic, or medical device trial within 30 days prior to screening
6. Women who are pregnant, may become pregnant, or nursing
7. Presence of any other disease or condition that is interfering with the absorption, distribution, metabolism, or excretion of SAMe such as those with gastric bypass surgery
8. Subjects with history of/diagnosis of hepatocellular carcinoma
9. Members from the same family of study participant. This is based on the recent paper on the non-random sampling in randomized controlled trials4. We acknowledge that if we assign family members to identical treatment, randomization would not be totally correct; but if properly randomized, there is a chance that the members of the family might mix the pills. To avoid this issue and maintain the integrity of randomized blinded fashion, we will not include members from the same family into the study
10. Subjects with psychiatric illnesses such as bipolar disorders as SAMe may interfere with the levels of anti-psychotic drugs and
11. Subjects who are immunocompromised

Exclusion criteria for all healthy control participants:

1. subjects with an active and serious medical disease
2. subjects with an infectious disease
3. consume any alcohol within 3 months before the study
4. subjects with localized or systemic infection

Where it's running

  • Cedars-Sinai Medical Center
    Los Angeles, California, United States
    Recruiting
  • Indiana University Hospital
    Indianapolis, Indiana, United States
    Recruiting

Study contacts

  • Principal investigator: Suthat Liangpunsakul, MD — Indiana University
  • Study coordinator: Maggie Hesler, B.S
  • Email: mshesler@iu.edu
  • Phone: (317) 988-4545

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

  • Optimizing recovery in patients with alcohol-related liver cirrhosis

    This study is testing if motivational interviews along with regular care can help people with alcohol-related liver cirrhosis improve their liver function and slow down the disease.

    Recruiting Copenhagen University Hospital, Hvidovre · Hvidovre, Capital Region · NCT06866496

  • Evaluating Cellgram-LC for Alcoholic Cirrhosis Treatment

    This study is testing whether a new treatment using stem cells can help people with alcoholic cirrhosis feel better and improve their liver health.

    Recruiting at 12 sites Phase 3 Pharmicell Co., Ltd. · Ansan and 14 other locations · NCT04689152

  • Understanding genetic factors in alcoholic liver disease

    This study looks at how common alcoholic hepatitis is in people with jaundice and tries to understand the role of genetics in the disease while also testing new ways to diagnose it.

    Recruiting at 9 sites University Hospital, Lille · Angers and 8 other locations · NCT04106518

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.